These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
12. Placental growth factor reverses decreased vascular and uteroplacental MMP-2 and MMP-9 and increased MMP-1 and MMP-7 and collagen types I and IV in hypertensive pregnancy. Ren Z; Cui N; Zhu M; Khalil RA Am J Physiol Heart Circ Physiol; 2018 Jul; 315(1):H33-H47. PubMed ID: 29569955 [TBL] [Abstract][Full Text] [Related]
13. Exosomes From Women With Preeclampsia Induced Vascular Dysfunction by Delivering sFlt (Soluble Fms-Like Tyrosine Kinase)-1 and sEng (Soluble Endoglin) to Endothelial Cells. Chang X; Yao J; He Q; Liu M; Duan T; Wang K Hypertension; 2018 Dec; 72(6):1381-1390. PubMed ID: 30571229 [TBL] [Abstract][Full Text] [Related]
14. Activating Transcription Factor 3 Is Reduced in Preeclamptic Placentas and Negatively Regulates sFlt-1 (Soluble fms-Like Tyrosine Kinase 1), Soluble Endoglin, and Proinflammatory Cytokines in Placenta. Kaitu'u-Lino TJ; Brownfoot FC; Hastie R; Chand A; Cannon P; Deo M; Tuohey L; Whitehead C; Hannan NJ; Tong S Hypertension; 2017 Nov; 70(5):1014-1024. PubMed ID: 28947613 [TBL] [Abstract][Full Text] [Related]
15. Combining metformin and sulfasalazine additively reduces the secretion of antiangiogenic factors from the placenta: Implications for the treatment of preeclampsia. Brownfoot FC; Hastie R; Hannan NJ; Cannon P; Nguyen TV; Tuohey L; Cluver C; Tong S; Kaitu'u-Lino TJ Placenta; 2020 Jun; 95():78-83. PubMed ID: 32452405 [TBL] [Abstract][Full Text] [Related]
16. YC-1 reduces placental sFlt-1 and soluble endoglin production and decreases endothelial dysfunction: A possible therapeutic for preeclampsia. Brownfoot FC; Tong S; Hannan NJ; Hastie R; Cannon P; Tuohey L; Kaitu'u-Lino TJ Mol Cell Endocrinol; 2015 Sep; 413():202-8. PubMed ID: 26159901 [TBL] [Abstract][Full Text] [Related]
17. Melatonin enhances antioxidant molecules in the placenta, reduces secretion of soluble fms-like tyrosine kinase 1 (sFLT) from primary trophoblast but does not rescue endothelial dysfunction: An evaluation of its potential to treat preeclampsia. Hannan NJ; Binder NK; Beard S; Nguyen TV; Kaitu'u-Lino TJ; Tong S PLoS One; 2018; 13(4):e0187082. PubMed ID: 29641523 [TBL] [Abstract][Full Text] [Related]
18. Human umbilical cord mesenchymal stem cell derived exosomes (HUCMSC-exos) recovery soluble fms-like tyrosine kinase-1 (sFlt-1)-induced endothelial dysfunction in preeclampsia. Chang X; He Q; Wei M; Jia L; Wei Y; Bian Y; Duan T; Wang K Eur J Med Res; 2023 Aug; 28(1):277. PubMed ID: 37559150 [TBL] [Abstract][Full Text] [Related]
19. Molecular hydrogen ameliorates several characteristics of preeclampsia in the Reduced Uterine Perfusion Pressure (RUPP) rat model. Ushida T; Kotani T; Tsuda H; Imai K; Nakano T; Hirako S; Ito Y; Li H; Mano Y; Wang J; Miki R; Yamamoto E; Iwase A; Bando YK; Hirayama M; Ohno K; Toyokuni S; Kikkawa F Free Radic Biol Med; 2016 Dec; 101():524-533. PubMed ID: 27789293 [TBL] [Abstract][Full Text] [Related]
20. Resveratrol inhibits release of soluble fms-like tyrosine kinase (sFlt-1) and soluble endoglin and improves vascular dysfunction - implications as a preeclampsia treatment. Hannan NJ; Brownfoot FC; Cannon P; Deo M; Beard S; Nguyen TV; Palmer KR; Tong S; Kaitu'u-Lino TJ Sci Rep; 2017 May; 7(1):1819. PubMed ID: 28500309 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]